199 related articles for article (PubMed ID: 11369829)
1. Effect of angiotensin II receptor blockade on renal disease progression in patients with non-diabetic chronic renal failure.
Mora-Macía J; Cases A; Calero F; Barceló P
Nephrol Dial Transplant; 2001; 16 Suppl 1():82-4. PubMed ID: 11369829
[TBL] [Abstract][Full Text] [Related]
2. Add-on angiotensin receptor blockade with maximized ACE inhibition.
Agarwal R
Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
[TBL] [Abstract][Full Text] [Related]
3. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
Iino Y; Hayashi M; Kawamura T; Shiigai T; Tomino Y; Yamada K; Kitajima T; Ideura T; Koyama A; Sugisaki T; Suzuki H; Umemura S; Kawaguchi Y; Uchida S; Kuwahara M; Yamazaki T;
Clin Exp Nephrol; 2003 Sep; 7(3):221-30. PubMed ID: 14586719
[TBL] [Abstract][Full Text] [Related]
4. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
Agarwal R; Siva S; Dunn SR; Sharma K
Am J Kidney Dis; 2002 Mar; 39(3):486-92. PubMed ID: 11877567
[TBL] [Abstract][Full Text] [Related]
5. Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade.
Agarwal R
Am J Physiol Renal Physiol; 2003 Apr; 284(4):F863-9. PubMed ID: 12505865
[TBL] [Abstract][Full Text] [Related]
6. The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA.
Schmidt A; Gruber U; Böhmig G; Köller E; Mayer G
Nephrol Dial Transplant; 2001 May; 16(5):1034-7. PubMed ID: 11328912
[TBL] [Abstract][Full Text] [Related]
7. Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial.
Praga M; Andrade CF; Luño J; Arias M; Poveda R; Mora J; Prat MV; Rivera F; Galceran JM; Ara JM; Aguirre R; Bernis C; Marín R; Campistol JM
Nephrol Dial Transplant; 2003 Sep; 18(9):1806-13. PubMed ID: 12937228
[TBL] [Abstract][Full Text] [Related]
8. [Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan].
Cice G; Ferrara L; Tagliamonte E; Russo PE; Di Benedetto A; Iacono A
Cardiologia; 1999 Dec; 44(12):1071-6. PubMed ID: 10687258
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin II type 1 (AT1) receptor antagonists in the treatment of hypertension after renal transplantation.
Holgado R; Anaya F; Del Castillo D
Nephrol Dial Transplant; 2001; 16 Suppl 1():117-20. PubMed ID: 11369838
[TBL] [Abstract][Full Text] [Related]
10. Effect of Lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies.
Cinotti GA; Zucchelli PC;
Nephrol Dial Transplant; 2001 May; 16(5):961-6. PubMed ID: 11328901
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment.
Usta M; Ersoy A; Dilek K; Ozdemir B; Yavuz M; Güllülü M; Yurtkuran M
J Intern Med; 2003 Mar; 253(3):329-34. PubMed ID: 12603500
[TBL] [Abstract][Full Text] [Related]
12. Long-term anti-proteinuric effect of Losartan in renal transplant recipients treated for hypertension.
Calviño J; Lens XM; Romero R; Sánchez-Guisande D
Nephrol Dial Transplant; 2000 Jan; 15(1):82-6. PubMed ID: 10607772
[TBL] [Abstract][Full Text] [Related]
13. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation.
Tylicki L; Rutkowski P; Renke M; Rutkowski B
Am J Nephrol; 2002; 22(4):356-62. PubMed ID: 12169868
[TBL] [Abstract][Full Text] [Related]
14. Differing anti-proteinuric action of candesartan and losartan in chronic renal disease.
Matsuda H; Hayashi K; Homma K; Yoshioka K; Kanda T; Takamatsu I; Tatematsu S; Wakino S; Saruta T
Hypertens Res; 2003 Nov; 26(11):875-80. PubMed ID: 14714578
[TBL] [Abstract][Full Text] [Related]
15. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF
J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
[TBL] [Abstract][Full Text] [Related]
16. Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy.
Andersen S; Jacobsen P; Tarnow L; Rossing P; Juhl TR; Parving HH
Nephrol Dial Transplant; 2003 Feb; 18(2):293-7. PubMed ID: 12543883
[TBL] [Abstract][Full Text] [Related]
17. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Parving HH; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S;
N Engl J Med; 2001 Sep; 345(12):861-9. PubMed ID: 11565518
[TBL] [Abstract][Full Text] [Related]
18. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
19. Decline of renal function is associated with proteinuria and systolic blood pressure in the morning in diabetic nephropathy.
Suzuki H; Kanno Y; Nakamoto H; Okada H; Sugahara S
Clin Exp Hypertens; 2005; 27(2-3):129-38. PubMed ID: 15835375
[TBL] [Abstract][Full Text] [Related]
20. Long-term antiproteinuric and renoprotective efficacy and safety of losartan in children with proteinuria.
Ellis D; Vats A; Moritz ML; Reitz S; Grosso MJ; Janosky JE
J Pediatr; 2003 Jul; 143(1):89-97. PubMed ID: 12915830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
